Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 10 of 10 entries
Sorted by: Best Match Show Resources per page
Erratum: New insights and new hope for pulmonary arterial hypertension: natriuretic peptides clearance receptor as a novel therapeutic target for a complex disease.

International journal of physiology, pathophysiology and pharmacology

Egom EE, Feridooni T, Pharithi RB, Khan B, Shiwani HA, Maher V, El Hiani Y, Rose RA, Pasumarthi KB, Ribama HA.
PMID: 29218116
Int J Physiol Pathophysiol Pharmacol. 2017 Nov 01;9(5):164. eCollection 2017.

[This corrects the article on p. 112 in vol. 9, PMID: 28951773.].

Cite
Egom EE, Feridooni T, Pharithi RB, et al. Erratum: New insights and new hope for pulmonary arterial hypertension: natriuretic peptides clearance receptor as a novel therapeutic target for a complex disease. Int J Physiol Pathophysiol Pharmacol. 2017;9(5):164
Egom, E. E., Feridooni, T., Pharithi, R. B., Khan, B., Shiwani, H. A., Maher, V., El Hiani, Y., Rose, R. A., Pasumarthi, K. B., & Ribama, H. A. (2017). Erratum: New insights and new hope for pulmonary arterial hypertension: natriuretic peptides clearance receptor as a novel therapeutic target for a complex disease. International journal of physiology, pathophysiology and pharmacology, 9(5), 164.
Egom, Emmanuel Eroume-A, et al. "Erratum: New insights and new hope for pulmonary arterial hypertension: natriuretic peptides clearance receptor as a novel therapeutic target for a complex disease." International journal of physiology, pathophysiology and pharmacology vol. 9,5 (2017): 164.
Egom EE, Feridooni T, Pharithi RB, Khan B, Shiwani HA, Maher V, El Hiani Y, Rose RA, Pasumarthi KB, Ribama HA. Erratum: New insights and new hope for pulmonary arterial hypertension: natriuretic peptides clearance receptor as a novel therapeutic target for a complex disease. Int J Physiol Pathophysiol Pharmacol. 2017 Nov 01;9(5):164. eCollection 2017. PMID: 29218116; PMCID: PMC5698694.
Copy Download .nbib Format: NLM
The Two Challenges in Management of Gastric Glomus Tumors.

Cureus

Mago S, Pasumarthi A, Miller DR, Saade R, Tadros M.
PMID: 32821597
Cureus. 2020 Jul 17;12(7):e9251. doi: 10.7759/cureus.9251.

Gastric glomus tumors (GGTs) are rare gastrointestinal lesions originating from the neuromuscular arterial canal or vascular lumen which share many overlapping features with other stromal lesions. Despite most cases of GGTs being benign, there is a lack of reliable...

Cite
Mago S, Pasumarthi A, Miller DR, et al. The Two Challenges in Management of Gastric Glomus Tumors. Cureus. 2020;12(7):e9251doi: 10.7759/cureus.9251.
Mago, S., Pasumarthi, A., Miller, D. R., Saade, R., & Tadros, M. (2020). The Two Challenges in Management of Gastric Glomus Tumors. Cureus, 12(7), e9251. https://doi.org/10.7759/cureus.9251
Mago, Sheena, et al. "The Two Challenges in Management of Gastric Glomus Tumors." Cureus vol. 12,7 (2020): e9251. doi: https://doi.org/10.7759/cureus.9251
Mago S, Pasumarthi A, Miller DR, Saade R, Tadros M. The Two Challenges in Management of Gastric Glomus Tumors. Cureus. 2020 Jul 17;12(7):e9251. doi: 10.7759/cureus.9251. PMID: 32821597; PMCID: PMC7430658.
Copy Download .nbib Format: NLM
Screening and Identification of Potential iNOS Inhibitors to Curtail Cervical Cancer Progression: an In Silico Drug Repurposing Approach.

Applied biochemistry and biotechnology

Poleboyina PK, Rampogu S, Doneti R, Pasha A, Poleboyina SM, Bhanothu S, Pasumarthi D, S D A, Kumbhakar D, Lee KW, Pawar SC.
PMID: 34705247
Appl Biochem Biotechnol. 2021 Oct 27; doi: 10.1007/s12010-021-03718-2. Epub 2021 Oct 27.

Cervical cancer is the second most common cause of cancer deaths in women worldwide and remains the main reason of mortality among women of reproductive age in developing countries. Nitric oxide is involved in several physiological functions inclusive of...

Cite
Poleboyina PK, Rampogu S, Doneti R, et al. Screening and Identification of Potential iNOS Inhibitors to Curtail Cervical Cancer Progression: an In Silico Drug Repurposing Approach. Appl Biochem Biotechnol. 2021;doi: 10.1007/s12010-021-03718-2.
Poleboyina, P. K., Rampogu, S., Doneti, R., Pasha, A., Poleboyina, S. M., Bhanothu, S., Pasumarthi, D., S D, A., Kumbhakar, D., Lee, K. W., & Pawar, S. C. (2021). Screening and Identification of Potential iNOS Inhibitors to Curtail Cervical Cancer Progression: an In Silico Drug Repurposing Approach. Applied biochemistry and biotechnology, . https://doi.org/10.1007/s12010-021-03718-2
Poleboyina, Pavan Kumar, et al. "Screening and Identification of Potential iNOS Inhibitors to Curtail Cervical Cancer Progression: an In Silico Drug Repurposing Approach." Applied biochemistry and biotechnology vol. (2021). doi: https://doi.org/10.1007/s12010-021-03718-2
Poleboyina PK, Rampogu S, Doneti R, Pasha A, Poleboyina SM, Bhanothu S, Pasumarthi D, S D A, Kumbhakar D, Lee KW, Pawar SC. Screening and Identification of Potential iNOS Inhibitors to Curtail Cervical Cancer Progression: an In Silico Drug Repurposing Approach. Appl Biochem Biotechnol. 2021 Oct 27; doi: 10.1007/s12010-021-03718-2. Epub 2021 Oct 27. PMID: 34705247.
Copy Download .nbib Format: NLM
A Cardiac Mitochondrial FGFR1 Mediates the Antithetical Effects of FGF2 Isoforms on Permeability Transition.

Cells

Srisakuldee W, Nickel BE, Fandrich RR, Zhang F, Pasumarthi KBS, Kardami E.
PMID: 34685716
Cells. 2021 Oct 13;10(10). doi: 10.3390/cells10102735.

Mitochondria, abundant organelles in high energy demand cells such as cardiomyocytes, can determine cell death or survival by regulating the opening of mitochondrial permeability transition pore, mPTP. We addressed the hypothesis that the growth factor FGF2, known to reside...

Cite
Srisakuldee W, Nickel BE, Fandrich RR, et al. A Cardiac Mitochondrial FGFR1 Mediates the Antithetical Effects of FGF2 Isoforms on Permeability Transition. Cells. 2021;10(10)doi: 10.3390/cells10102735.
Srisakuldee, W., Nickel, B. E., Fandrich, R. R., Zhang, F., Pasumarthi, K. B. S., & Kardami, E. (2021). A Cardiac Mitochondrial FGFR1 Mediates the Antithetical Effects of FGF2 Isoforms on Permeability Transition. Cells, 10(10), . https://doi.org/10.3390/cells10102735
Srisakuldee, Wattamon, et al. "A Cardiac Mitochondrial FGFR1 Mediates the Antithetical Effects of FGF2 Isoforms on Permeability Transition." Cells vol. 10,10 (2021). doi: https://doi.org/10.3390/cells10102735
Srisakuldee W, Nickel BE, Fandrich RR, Zhang F, Pasumarthi KBS, Kardami E. A Cardiac Mitochondrial FGFR1 Mediates the Antithetical Effects of FGF2 Isoforms on Permeability Transition. Cells. 2021 Oct 13;10(10). doi: 10.3390/cells10102735. PMID: 34685716; PMCID: PMC8534529.
Copy Download .nbib Format: NLM
Differentiating Delayed Esophageal Clearance From Reflux in Scleroderma.

Cureus

Pasumarthi A, Mago S, Banerjee P, Tadros M.
PMID: 33365221
Cureus. 2020 Nov 18;12(11):e11553. doi: 10.7759/cureus.11553.

Abnormal acid exposure to the esophagus and esophageal dysmotility leading to symptoms of refractory reflux and dysphagia are common findings amongst patients with advanced systemic scleroderma (SSc). Although treatments and diagnostic methods for esophageal disease in the setting of...

Cite
Pasumarthi A, Mago S, Banerjee P, et al. Differentiating Delayed Esophageal Clearance From Reflux in Scleroderma. Cureus. 2020;12(11):e11553doi: 10.7759/cureus.11553.
Pasumarthi, A., Mago, S., Banerjee, P., & Tadros, M. (2020). Differentiating Delayed Esophageal Clearance From Reflux in Scleroderma. Cureus, 12(11), e11553. https://doi.org/10.7759/cureus.11553
Pasumarthi, Anusha, et al. "Differentiating Delayed Esophageal Clearance From Reflux in Scleroderma." Cureus vol. 12,11 (2020): e11553. doi: https://doi.org/10.7759/cureus.11553
Pasumarthi A, Mago S, Banerjee P, Tadros M. Differentiating Delayed Esophageal Clearance From Reflux in Scleroderma. Cureus. 2020 Nov 18;12(11):e11553. doi: 10.7759/cureus.11553. PMID: 33365221; PMCID: PMC7748571.
Copy Download .nbib Format: NLM
Elective Surgical Experience During COVID Pandemic at a Tertiary Cancer Care Centre in India: A Retrospective Analysis.

Indian journal of surgical oncology

Nagarkar R, Roy S, Dhondge R, Adhav A, Manke A, Banswal L, Upwanshi M, Kulkarni N, Tandale R, Bang Y, Pasumarthi LS, Subramaniam A, Rajpari KN, Yajurvedi P, Ansari S, Wankhede B, Ramesh YV.
PMID: 34421277
Indian J Surg Oncol. 2021 Aug 16;1-8. doi: 10.1007/s13193-021-01403-8. Epub 2021 Aug 16.

To analyse and identify possible outcomes of elective cancer surgeries performed at a tertiary cancer centre during COVID19 pandemic. This is a retrospective study including patients that underwent surgery at HCG Manavata cancer centre, Nashik, Maharashtra, India, from 15...

Cite
Nagarkar R, Roy S, Dhondge R, et al. Elective Surgical Experience During COVID Pandemic at a Tertiary Cancer Care Centre in India: A Retrospective Analysis. Indian J Surg Oncol. 2021;1-8doi: 10.1007/s13193-021-01403-8.
Nagarkar, R., Roy, S., Dhondge, R., Adhav, A., Manke, A., Banswal, L., Upwanshi, M., Kulkarni, N., Tandale, R., Bang, Y., Pasumarthi, L. S., Subramaniam, A., Rajpari, K. N., Yajurvedi, P., Ansari, S., Wankhede, B., & Ramesh, Y. V. (2021). Elective Surgical Experience During COVID Pandemic at a Tertiary Cancer Care Centre in India: A Retrospective Analysis. Indian journal of surgical oncology, 1-8. https://doi.org/10.1007/s13193-021-01403-8
Nagarkar, Raj, et al. "Elective Surgical Experience During COVID Pandemic at a Tertiary Cancer Care Centre in India: A Retrospective Analysis." Indian journal of surgical oncology vol. (2021): 1-8. doi: https://doi.org/10.1007/s13193-021-01403-8
Nagarkar R, Roy S, Dhondge R, Adhav A, Manke A, Banswal L, Upwanshi M, Kulkarni N, Tandale R, Bang Y, Pasumarthi LS, Subramaniam A, Rajpari KN, Yajurvedi P, Ansari S, Wankhede B, Ramesh YV. Elective Surgical Experience During COVID Pandemic at a Tertiary Cancer Care Centre in India: A Retrospective Analysis. Indian J Surg Oncol. 2021 Aug 16;1-8. doi: 10.1007/s13193-021-01403-8. Epub 2021 Aug 16. PMID: 34421277; PMCID: PMC8365133.
Copy Download .nbib Format: NLM
New insights and new hope for pulmonary arterial hypertension: natriuretic peptides clearance receptor as a novel therapeutic target for a complex disease.

International journal of physiology, pathophysiology and pharmacology

Egom EE, Feridooni T, Pharithi RB, Khan B, Shiwani HA, Maher V, El Hiani Y, Rose RA, Pasumarthi KB, Ribama HA.
PMID: 28951773
Int J Physiol Pathophysiol Pharmacol. 2017 Sep 01;9(4):112-118. eCollection 2017.

BACKGROUND: Pulmonary Arterial Hypertension (PAH) is a deadly and disabling disease for which there is no marketed drug that addresses the underlying disease mechanism and targets to cure patients. The lack of understanding of the disease mechanism represents the...

Cite
Egom EE, Feridooni T, Pharithi RB, et al. New insights and new hope for pulmonary arterial hypertension: natriuretic peptides clearance receptor as a novel therapeutic target for a complex disease. Int J Physiol Pathophysiol Pharmacol. 2017;9(4):112-118
Egom, E. E., Feridooni, T., Pharithi, R. B., Khan, B., Shiwani, H. A., Maher, V., El Hiani, Y., Rose, R. A., Pasumarthi, K. B., & Ribama, H. A. (2017). New insights and new hope for pulmonary arterial hypertension: natriuretic peptides clearance receptor as a novel therapeutic target for a complex disease. International journal of physiology, pathophysiology and pharmacology, 9(4), 112-118.
Egom, Emmanuel Eroume-A, et al. "New insights and new hope for pulmonary arterial hypertension: natriuretic peptides clearance receptor as a novel therapeutic target for a complex disease." International journal of physiology, pathophysiology and pharmacology vol. 9,4 (2017): 112-118.
Egom EE, Feridooni T, Pharithi RB, Khan B, Shiwani HA, Maher V, El Hiani Y, Rose RA, Pasumarthi KB, Ribama HA. New insights and new hope for pulmonary arterial hypertension: natriuretic peptides clearance receptor as a novel therapeutic target for a complex disease. Int J Physiol Pathophysiol Pharmacol. 2017 Sep 01;9(4):112-118. eCollection 2017. PMID: 28951773; PMCID: PMC5592245.
Copy Download .nbib Format: NLM
Screening and Identification of Potential iNOS Inhibitors to Curtail Cervical Cancer Progression: an In Silico Drug Repurposing Approach.

Applied biochemistry and biotechnology

Poleboyina PK, Rampogu S, Doneti R, Pasha A, Poleboyina SM, Bhanothu S, Pasumarthi D, S D A, Kumbhakar D, Lee KW, Pawar SC.
PMID: 34705247
Appl Biochem Biotechnol. 2022 Jan;194(1):570-586. doi: 10.1007/s12010-021-03718-2. Epub 2021 Oct 27.

Cervical cancer is the second most common cause of cancer deaths in women worldwide and remains the main reason of mortality among women of reproductive age in developing countries. Nitric oxide is involved in several physiological functions inclusive of...

Cite
Poleboyina PK, Rampogu S, Doneti R, et al. Screening and Identification of Potential iNOS Inhibitors to Curtail Cervical Cancer Progression: an In Silico Drug Repurposing Approach. Appl Biochem Biotechnol. 2021;194(1):570-586doi: 10.1007/s12010-021-03718-2.
Poleboyina, P. K., Rampogu, S., Doneti, R., Pasha, A., Poleboyina, S. M., Bhanothu, S., Pasumarthi, D., S D, A., Kumbhakar, D., Lee, K. W., & Pawar, S. C. (2022). Screening and Identification of Potential iNOS Inhibitors to Curtail Cervical Cancer Progression: an In Silico Drug Repurposing Approach. Applied biochemistry and biotechnology, 194(1), 570-586. https://doi.org/10.1007/s12010-021-03718-2
Poleboyina, Pavan Kumar, et al. "Screening and Identification of Potential iNOS Inhibitors to Curtail Cervical Cancer Progression: an In Silico Drug Repurposing Approach." Applied biochemistry and biotechnology vol. 194,1 (2022): 570-586. doi: https://doi.org/10.1007/s12010-021-03718-2
Poleboyina PK, Rampogu S, Doneti R, Pasha A, Poleboyina SM, Bhanothu S, Pasumarthi D, S D A, Kumbhakar D, Lee KW, Pawar SC. Screening and Identification of Potential iNOS Inhibitors to Curtail Cervical Cancer Progression: an In Silico Drug Repurposing Approach. Appl Biochem Biotechnol. 2022 Jan;194(1):570-586. doi: 10.1007/s12010-021-03718-2. Epub 2021 Oct 27. PMID: 34705247.
Copy Download .nbib Format: NLM
Regulation of Transplanted Cell Homing by FGF1 and PDGFB after Doxorubicin Myocardial Injury.

Cells

Baguma-Nibasheka M, Feridooni T, Zhang F, Pasumarthi KBS.
PMID: 34831221
Cells. 2021 Nov 03;10(11). doi: 10.3390/cells10112998.

There is no effective treatment for the total recovery of myocardial injury caused by an anticancer drug, doxorubicin (Dox). In this study, using a Dox-induced cardiac injury model, we compared the cardioprotective effects of ventricular cells harvested from 11.5-day...

Cite
Baguma-Nibasheka M, Feridooni T, Zhang F, et al. Regulation of Transplanted Cell Homing by FGF1 and PDGFB after Doxorubicin Myocardial Injury. Cells. 2021;10(11)doi: 10.3390/cells10112998.
Baguma-Nibasheka, M., Feridooni, T., Zhang, F., & Pasumarthi, K. B. S. (2021). Regulation of Transplanted Cell Homing by FGF1 and PDGFB after Doxorubicin Myocardial Injury. Cells, 10(11), . https://doi.org/10.3390/cells10112998
Baguma-Nibasheka, Mark, et al. "Regulation of Transplanted Cell Homing by FGF1 and PDGFB after Doxorubicin Myocardial Injury." Cells vol. 10,11 (2021). doi: https://doi.org/10.3390/cells10112998
Baguma-Nibasheka M, Feridooni T, Zhang F, Pasumarthi KBS. Regulation of Transplanted Cell Homing by FGF1 and PDGFB after Doxorubicin Myocardial Injury. Cells. 2021 Nov 03;10(11). doi: 10.3390/cells10112998. PMID: 34831221; PMCID: PMC8616453.
Copy Download .nbib Format: NLM
Screening and Identification of Potential iNOS Inhibitors to Curtail Cervical Cancer Progression: an In Silico Drug Repurposing Approach.

Applied biochemistry and biotechnology

Poleboyina PK, Rampogu S, Doneti R, Pasha A, Poleboyina SM, Bhanothu S, Pasumarthi D, S D A, Kumbhakar D, Lee KW, Pawar SC.
PMID: 34705247
Appl Biochem Biotechnol. 2022 Jan;194(1):570-586. doi: 10.1007/s12010-021-03718-2. Epub 2021 Oct 27.

Cervical cancer is the second most common cause of cancer deaths in women worldwide and remains the main reason of mortality among women of reproductive age in developing countries. Nitric oxide is involved in several physiological functions inclusive of...

Cite
Poleboyina PK, Rampogu S, Doneti R, et al. Screening and Identification of Potential iNOS Inhibitors to Curtail Cervical Cancer Progression: an In Silico Drug Repurposing Approach. Appl Biochem Biotechnol. 2021;194(1):570-586doi: 10.1007/s12010-021-03718-2.
Poleboyina, P. K., Rampogu, S., Doneti, R., Pasha, A., Poleboyina, S. M., Bhanothu, S., Pasumarthi, D., S D, A., Kumbhakar, D., Lee, K. W., & Pawar, S. C. (2022). Screening and Identification of Potential iNOS Inhibitors to Curtail Cervical Cancer Progression: an In Silico Drug Repurposing Approach. Applied biochemistry and biotechnology, 194(1), 570-586. https://doi.org/10.1007/s12010-021-03718-2
Poleboyina, Pavan Kumar, et al. "Screening and Identification of Potential iNOS Inhibitors to Curtail Cervical Cancer Progression: an In Silico Drug Repurposing Approach." Applied biochemistry and biotechnology vol. 194,1 (2022): 570-586. doi: https://doi.org/10.1007/s12010-021-03718-2
Poleboyina PK, Rampogu S, Doneti R, Pasha A, Poleboyina SM, Bhanothu S, Pasumarthi D, S D A, Kumbhakar D, Lee KW, Pawar SC. Screening and Identification of Potential iNOS Inhibitors to Curtail Cervical Cancer Progression: an In Silico Drug Repurposing Approach. Appl Biochem Biotechnol. 2022 Jan;194(1):570-586. doi: 10.1007/s12010-021-03718-2. Epub 2021 Oct 27. PMID: 34705247.
Copy Download .nbib Format: NLM
Showing 1 to 10 of 10 entries